IMMAGE BIOTHERAPEUTICS CORP.: 10-Q filed 2017-01-06
What IMMAGE BIOTHERAPEUTICS CORP. reported in its quarterly report filed 2017-01-06 (fiscal Q1 2017): 16 published measures, 31 facts as tagged in accession 0001640334-17-000020.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2017-01-06
- Fiscal period
- fiscal Q1 2017
- Accession
- 0001640334-17-000020 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All IMMAGE BIOTHERAPEUTICS CORP. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-11-30 | 168,892 | USD | |
| At 2016-08-31 | 243,104 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-11-30 | 102,456 | USD | |
| At 2016-08-31 | 55,816 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-11-30 | 66,436 | USD | |
| At 2016-08-31 | 187,288 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-11-30 | 127,135 | USD | |
| At 2016-08-31 | 196,715 | USD | |
| At 2015-11-30 | 383,619 | USD | |
| At 2015-08-31 | 32,678 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-09-01 to 2016-11-30 | -1,670,852 | USD | 91 |
| 2015-09-01 to 2015-11-30 | -34,026 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-11-30 | -1,973,684 | USD | |
| At 2016-08-31 | -302,832 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-11-30 | 30,105 | USD | |
| At 2016-08-31 | 32,158 | USD |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-11-30 | 132,968 | USD | |
| At 2016-08-31 | 205,048 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-09-01 to 2015-11-30 | 801 | USD | 91 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-11-30 | 102,456 | USD | |
| At 2016-08-31 | 55,816 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-09-01 to 2016-11-30 | 1,670,852 | USD | 91 |
| 2015-09-01 to 2015-11-30 | 33,225 | USD | 91 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-09-01 to 2016-11-30 | 1,625,066 | USD | 91 |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-11-30 | 5,819 | USD | |
| At 2016-08-31 | 5,898 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-09-01 to 2016-11-30 | 27,962 | USD | 91 |
| 2015-09-01 to 2015-11-30 | 19,796 | USD | 91 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-09-01 to 2015-11-30 | -801 | USD | 91 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-09-01 to 2016-11-30 | 45,140 | USD | 91 |
| 2015-09-01 to 2015-11-30 | 4,447 | USD | 91 |
Inspect the source
- Entity
- IMMAGE BIOTHERAPEUTICS CORP. / CIK 0001564273
- Captured
- SEC response SHA-256
76b05bb10042aafcff9e5410669c161498d0cb2a1a3e0078501d457e3630a630
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001564273.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))